Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com
Oral Decitabine Plus Cedazuridine Combo Shows Promise in Lower-Risk MDS
January 12th 2022James K. McCloskey, MD, discusses the efficacy of oral decitabine plus cedazuridine, the combination’s potential role in lower-risk myelodysplastic syndromes, and what this could mean for the patient population.
Read More
Larkin Unpacks the Effect of Anti–PD-L1 Therapy on TIL Activity in Melanoma
December 7th 2021The role of adoptive cell therapy with tumor-infiltrating lymphocytes for patients with melanoma has undergone scrutiny as efforts to unpack the correlation between the duration of prior immunotherapy and efficacy outcomes.
Read More
Tebentafusp Represents a Potential Frontline Therapy for Patients with Uveal Melanoma
December 2nd 2021Richard D. Carvajal, MD, discusses the need for additional treatment options in patients with rare melanomas, the promise of tebentafusp, and ongoing trials in the pipeline for this patient population.
Read More
De-Escalated Approaches Continue to Show Benefit in HER2+ Breast Cancer
December 2nd 2021Deborah L. Toppmeyer, MD, discusses clinical trials involving treatments for HER2-positive and triple-negative breast cancer, as well as the importance of making these trials accessible to all patient populations in an attempt to address disparities.
Read More
BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy
December 1st 2021The addition of BO-112 to pembrolizumab produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial.
Read More
De-Escalation Approaches Lead Shift Away From Toxic Standards in HER2+ Breast Cancer
November 22nd 2021Neil Vasan, MD, PhD, discussed the emergence of de-escalated treatment strategies for patients with HER2-positive breast cancer, pivotal trials that have shifted standards in clinical practice, and next steps for research.
Read More
Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination
November 22nd 2021Muhammad Bilal Abid, MD, discusses immune-compromising factors that are indigenous to CAR T-cell recipients, the immunogenic potential of different COVID-19 vaccines, determinants of response, and the potential need for booster strategies.
Read More
Ripretinib Continues to Provide Meaningful Clinical Benefit in Heavily Pretreated GIST
November 10th 2021John R. Zalcberg, MBBS, PhD, discusses the INVICTUS trial examining ripretinib in patients with heavily pretreated gastrointestinal stromal tumors, the impact of the agent on the paradigm, and ongoing efforts to provide additional options to this population.
Read More
Future of Lung Cancer Treatment Looks Bright With Emerging Technologies, Novel Discoveries
November 8th 2021Mark G. Kris, MD, discusses recent progress in non–small cell lung cancer and small cell lung cancer, efforts being made to address unmet needs in these paradigms, and ongoing research that is generating excitement.
Read More
Genomically-Guided Radiation Dosing Model Shows Promise in Various Cancer Types
November 3rd 2021Radiation oncologists Jacob Scott, MD, DPhil, and Javier Torres-Roca, MD, discuss the benefits of using GARD in a pooled pan-cancer analysis and why there is a call to action to integrate GARD-based radiotherapy dosing in oncology.
Read More
Larotrectinib Yields Promising Efficacy in NTRK+ Lung Cancer, Is Active Against CNS Metastases
October 30th 2021Jessica J. Lin, MD, discussed the impact of larotrectinib in patients with NTRK fusion–positive lung cancer, and the importance of further understanding mechanism of resistance to targeted therapies.
Read More
AMPLITUDE Trial Examines PARP Inhibition in HRR Gene–Mutated mCSPC
October 4th 2021Although the efficacy of PARP inhibitors has been established in patients with metastatic castration-resistant prostate cancer in previous studies, the use of these agents earlier on in the disease process has yet to be evaluated.
Read More
Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.
Read More
Frontline Pembrolizumab/Chemo Represents New Standard in Metastatic TNBC With PD-L1 CPS ≥10
September 28th 2021Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.
Read More
Acalabrutinib Continues to Showcase Impressive Activity in Relapsed/Refractory MCL
September 21st 2021Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.
Read More
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer
September 14th 2021Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
Read More